Male patient talking to doctor. CRFS after relugolix was not significantly different compared with leuprolide in men with advanced prostate cancer and metastatic disease. Castration resistance-free ...

XTANDI: the first and only androgen receptor inhibitor-based regimen to demonstrate overall survival benefit in non-metastatic hormone-sensitive prostate cancer (nmHSPC) with high-risk biochemical ...

Secondary endpoint data from the EMBARK trial support use of enzalutamide treatments in patients with high-risk biochemically recurrent prostate cancer.

(RTTNews) - Amneal Pharmaceuticals, Inc. (AMRX), an integrated essential medicines company, announced Wednesday that it has received Abbreviated New Drug Application or ANDA approval from the U.S.

New Delhi, Nov 14 (PTI) Zydus Lifesciences Ltd on Friday said it has received final approval from the US health regulator for its generic version of Leuprolide Acetate injection used in palliative ...

Mumbai, Nov. 14 -- Zydus Lifesciences has received final approval from the United States Food and Drug Administration (USFDA) for Leuprolide Acetate injection, 14 mg/2.8 mL (1 mg/0.2 mL) multiple-dose ...

Injectable luteinizing hormone–releasing hormone agonists (e.g., leuprolide) are the standard agents for achieving androgen deprivation for prostate cancer despite the initial testosterone surge and ...

BRIDGEWATER, N.J.--(BUSINESS WIRE)--Amneal Pharmaceuticals, Inc. (NYSE: AMRX) (“Amneal” or the “Company”) today announced that it has received Abbreviated New Drug Application (ANDA) approval from the ...